Roche-Genentech Community Letter: GENERATION HD2 Study Now Open

This study evaluates the safety, biomarkers and efficacy trends of different dose levels of investigational drug tominersen in people aged 25 to 50 with prodromal (very early subtle signs of HD) or early manifest HD.

CLICK HERE FOR FULL STATEMENT FROM ROCHE-GENENTECH